Clinical Trial Supplies Market

Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases, Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs), & Region - Global Forecast to 2028

Report Code: PH 3772 Oct, 2023, by marketsandmarkets.com

The global clinical trial supplies market in terms of revenue was estimated to be worth $3.9 billion in 2023 and is poised to reach $6.3 billion by 2028, growing at a CAGR of 9.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The clinical trials supplies market's growth is influenced by a combination of various factors such as increasing prevalence of diseases, rise in number of clinical trials and robust regulatory support for clinical trials. Furthermore, increasing industrial collaborations for drug development is likely to give momentum to clinical trials supplies market growth.

Attractive Opportunities in the Clinical Trial Supplies Market

Clinical Trial Supplies Market

To know about the assumptions considered for the study, Request for Free Sample Report

Clinical Trial Supplies Market

Global Clinical Trial Supplies Market Dynamics

Driver: Increasing the number of registered clinical trials

According to WHO, in 2022, there is a increase in number of registered clinical trials, almost 7,44,100 clinical studies registered globally. The United States of America had the highest total number of trials registered during 1999-2022 (168,520), followed by China (94,193) and Japan (63,499), on which of clinical trials with an identified phase of development, the largest number of trials is in phase II (95,790).

Among all industry sectors, the pharmaceutical industry spends the largest percentage of their revenue on R&D. Data for the last twenty three years of a continuous growth in the number of registered and active clinical trial cases. This is the major factor to a rise in outsourcing the clinical trial services such as manufacturing, packaging, labeling, blinding, and storage & delivery.

Restraint: High cost of drug development

The clinical trial supplies have various limitations, such as high cost of drug discovery and development.

However, research and development for some of the rare diseases are very high challenging and requires a skilled labourers to conduct clinical trials, and drug research and drug research and development process that can be prone to failure.

Opportunity: Growth opportunities in emerging markets

In clinical trial supplies market the North America and Europe, are the major hubs for clinical trial services. And these countries are facing a challenge of high cost of clinical trials for their innovative drug development. This has resulted in many cases of rare diseases and their clinical trials are being conducted by developing nations. Thermo Fisher Scientific Inc. (US) company One of the key players in this market, has announced the establishment of the PPD DCT Network to assist international researchers and research facilities taking part in DCTs for pharmaceutical and biotech clients. Catelent Inc. (US)  acquired Bomi Group to support the growth in healthcare logistics by expanding the companies international presence and increasing cold chain capabilities in major European and Latin American markets.

Challenge: The high cost of clinical trials is a major hindrance to the clinical trial supplies market growth

The huge cost of clinical trials process is a major challenge of the growth of clinical trial supplies market. Factors that contributes to the rising the costs of clinical trials is the increasing need to collect sufficient clinical data. This market analysis report also provides the detailed information about the upcoming trends and challenges that will have a far-reaching effect on the market growth in future. In clinical trial studies the research, and development (R&D) costs was very high.

The pharmaceutical and biotechnology companies segment accounted for the largest share of the clinical trial supplies industry in 2022

Based on end users, the clinical trial supplies market is further segmented into, pharmaceutical & biotechnology companies, contract research organizations (CROs), and medical device companies. In 2022, the pharmaceutical and biotechnology companies accounted for the largest share of this market. The segment held dominant share owing to increased investment in drug development and clinical trials.

North America was the largest regional market for Clinical trial supplies industry in 2022.

The clinical trial supplies market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. The globalization of clinical trials and rising investments in R&D for clinical trials in the north American region and rising strategic choices such as partnerships and collaboration for clinical trial services are some of the major factors contributing to the growth of market.

Clinical Trial Supplies Market Ecosystem

Clinical Trial Supplies Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the clinical trial supplies market include Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US), Nuvisan (Germany), Lonza Group (Switzerland), OCT Group LLC (US), Corex Logistic Limited (Ireland), Acnos Pharma GMBH (Germany), Clinical Service International (UK), Klifo (Denmark), Clinigen Limited (UK), Ancillare LP (US), N-Side (Europe), ADAllen pharma (UK), Durbin (UK), Recipharm AB (Sweden), IPS Pharma (UK).

Scope of the Clinical Trial Supplies Industry:

Report Metric

Details

Market Revenue in 2023

$3.9 billion

Estimated Value by 2028

$6.3 billion

Revenue Rate

Poised to grow at a CAGR of 9.9%

Market Driver

Increasing the number of registered clinical trials

Market Opportunity

Growth opportunities in emerging markets

This report categorizes the clinical trial supplies market to forecast revenue and analyze trends in each of the following submarkets:

By Service

  • Logistics & Distribution
  • Storage & Retention
  • Packaging, Labelling & Blinding
  • Manufacturing
  • Comparator Sourcing
  • Other Services (Solutions and Ancillary supplies)

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • BA/BE Studies

By Type

  • Small-Molecules
  • Biologic Drugs
  • Medical Devices

By Therapeutic Area

  • Oncology
  • Infectious Diseases
  • Neurology
  • Metabolic Disorders
  • Immunology
  • Cardiology
  • Genetic Diseases
  • Other Therapeutic Areas (Respiratory diseases, dermatological conditions, rare diseases, ENT diseases, and nephrology)

By End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organisations (CRO's)
  • Medical Device Companies

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • Netherlands
    • Rest of Europe (ROE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Singapore
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • RoLATAM
  • Middle East
  • Africa

Recent Developments Clinical Trial Supplies Industry

  • In July 2023, Thermo Fisher Scientific Inc. (US) has entered into collaboration with the national minority quality forum (NMQF), an independent non-profit dedicated to research and education. This collaboration facilitated through NMQF’s Alliance for Representative Clinical Trials (ARC), aims to improve the inclusion of historically underserved patient groups in clinical research.
  • In April 2023, Almac Group (UK), has introduced the IXRS®3 Partnership Network, designed to expedite the creation and deployment of advanced eClinical solutions for biopharmaceutical sponsors.
  • In March 2023, Icon Plc (Ireland) has entered into a strategic partnership with LEO Pharma (Denmark), and This collaboration aims to enhance LEO Pharma's clinical trial operations, focusing on patient-centricity and cost-efficiency. The goal is to strengthen LEO Pharma's
  • In August 2022, Marken (US) has acquired Bomi Group to support the growth in healthcare logistics by expanding the companies international presence and increasing cold chain capabilities in major European and Latin American markets.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 40)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 RESEARCH LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 45)
    2.1 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 PRIMARY RESEARCH
                    FIGURE 2 CLINICAL TRIAL SUPPLIES MARKET: PRIMARY RESPONDENTS
           2.1.2 SECONDARY DATA
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 CLINICAL TRIAL SUPPLIES INDUSTRY SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
           2.2.1 INSIGHTS FROM PRIMARY
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENTAL ASSESSMENT (BY SERVICE, PHASE, TYPE, THERAPEUTIC AREA, END USER, AND REGION)
                    FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS 
          FIGURE 7 MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
          FIGURE 8 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 STUDY ASSUMPTIONS 
    2.5 RISK ANALYSIS 
    2.6 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 57)
    FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 CLINICAL TRIAL SUPPLIES INDUSTRY, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 61)
    4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 
          FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES INDUSTRY, BY TYPE AND COUNTRY (2022) 
          FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 MARKET SHARE, BY SERVICE, 2023 VS. 2028 
          FIGURE 18 LOGISTICS & DISTRIBUTION SERVICES TO CONTINUE TO DOMINATE MARKET IN 2028
    4.4 MARKET SHARE, BY END USER, 2022 
          FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 65)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.3 CLINICAL TRIAL SUPPLIES INDUSTRY: IMPACT ANALYSIS 
           5.3.1 DRIVERS
                    5.3.1.1 Increasing R&D investments by biopharma companies
                                TABLE 4 R&D INVESTMENTS BY MAJOR PLAYERS (2022)
                    5.3.1.2 Growing number of clinical trials
                                FIGURE 22 NUMBER OF REGISTERED CLINICAL TRIALS (2011–2022)
                                FIGURE 23 ONGOING CLINICAL TRIALS, BY PHASE (% SHARE), 2022
                    5.3.1.3 Growing decentralization of clinical trials
                    5.3.1.4 Rising prevalence of orphan and rare diseases
                                FIGURE 24 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023)
                                FIGURE 25 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHED WITH ORPHAN DRUG DESIGNATION, 2012–2022
                    5.3.1.5 Increasing outsourcing activities in emerging Asian economies
           5.3.2 RESTRAINTS
                    5.3.2.1 High cost of drug development
           5.3.3 OPPORTUNITIES
                    5.3.3.1 Growth opportunities in emerging markets
                    5.3.3.2 Increased investments in development of biologics and biosimilars
                                FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022)
                                TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022
                                FIGURE 27 BIOSIMILAR APPROVALS AND LAUNCHES (2015–2022)
                    5.3.3.3 Rising demand for specialized testing services
           5.3.4 CHALLENGES
                    5.3.4.1 High cost of clinical trials
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 28 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
    5.5 PRICING ANALYSIS 
           5.5.1 INDICATIVE PRICING ANALYSIS OF OVERALL CLINICAL TRIALS, BY PHASE.
                    TABLE 6 PHASE III ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES)
                    TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN)
    5.6 TECHNOLOGY ANALYSIS 
           5.6.1 INTERACTIVE RESPONSE TECHNOLOGY (IRT)
    5.7 VALUE CHAIN ANALYSIS 
          FIGURE 29 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
    5.8 ECOSYSTEM ANALYSIS 
    5.9 SUPPLY CHAIN ANALYSIS 
          TABLE 8 MARKET: SUPPLY CHAIN ANALYSIS
    5.10 KEY CONFERENCES & EVENTS IN 2023–2024 
           TABLE 9 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.11 REGULATORY ANALYSIS 
           5.11.1 REGULATORY LANDSCAPE FOR CLINICAL TRIAL SUPPLIES
                    5.11.1.1 North America
                    5.11.1.2 Europe
                    5.11.1.3 Asia Pacific
                    5.11.1.4 Rest of the World
           5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 15 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 DEGREE OF COMPETITION
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SUPPLY SERVICES
           5.13.2 BUYING CRITERIA FOR CLINICAL TRIAL SUPPLY SERVICES
                     FIGURE 31 KEY BUYING CRITERIA FOR END USERS
 
6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE (Page No. - 94)
    6.1 INTRODUCTION 
          TABLE 16 CLINICAL TRIAL SUPPLIES INDUSTRY, BY SERVICE, 2021–2028 (USD MILLION)
    6.2 LOGISTICS & DISTRIBUTION 
           6.2.1 INCREASING COMPLEXITY AND EVOLVING TREATMENT PROTOCOLS TO DRIVE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES
                    TABLE 17 MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 18 NORTH AMERICA: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 EUROPE: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 ASIA PACIFIC: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 LATIN AMERICA: MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 STORAGE & RETENTION 
           6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH
                    TABLE 22 MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 23 NORTH AMERICA: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 EUROPE: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 LATIN AMERICA: MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 PACKAGING, LABELING, AND BLINDING 
           6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE SEGMENTAL GROWTH
                    TABLE 27 MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 28 NORTH AMERICA: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 EUROPE: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 ASIA PACIFIC: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 LATIN AMERICA: MARKET FOR LABELING, AND BLINDING SERVICES, COUNTRY, 2021–2028 (USD MILLION)
    6.5 MANUFACTURING 
           6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH
                    TABLE 32 MARKET FOR MANUFACTURING SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 33 NORTH AMERICA: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 EUROPE: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 LATIN AMERICA: MARKET FOR MANUFACTURING SERVICES, COUNTRY, 2021–2028 (USD MILLION)
    6.6 COMPARATOR SOURCING 
           6.6.1 INTENSE MARKET COMPETITION AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH
                    TABLE 37 MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 38 NORTH AMERICA: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 EUROPE: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 41 LATIN AMERICA: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.7 OTHER SERVICES 
          TABLE 42 MARKET FOR OTHER SERVICES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 43 NORTH AMERICA: MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 44 EUROPE: MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 45 ASIA PACIFIC: MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 46 LATIN AMERICA: MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE (Page No. - 114)
    7.1 INTRODUCTION 
          TABLE 47 CLINICAL TRIAL SUPPLIES INDUSTRY, BY PHASE, 2021–2028 (USD MILLION)
    7.2 PHASE III 
           7.2.1 LARGE PATIENT POPULATION ASSOCIATED WITH PHASE III TRIALS TO DRIVE DEMAND
                    TABLE 48 MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 EUROPE: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 52 LATIN AMERICA: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 PHASE II 
           7.3.1 ABILITY OF PHASE II CLINICAL TRIALS TO PROVIDE CLARITY ON EFFECTIVENESS AND SAFETY OF DRUGS TO DRIVE MARKET GROWTH
                    TABLE 53 MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 54 NORTH AMERICA: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 EUROPE: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 ASIA PACIFIC: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 LATIN AMERICA: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 PHASE I 
           7.4.1 IMPORTANCE OF QUALITY CLINICAL TRIAL SUPPLIES IN PHASE I CLINICAL TRIALS TO BOOST MARKET
                    TABLE 58 MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 LATIN AMERICA: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 PHASE IV 
           7.5.1 INCREASING NUMBER OF STUDIES UNDER PHASE IV TRIAL TO SUPPORT GROWTH
                    TABLE 63 MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 64 NORTH AMERICA: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 EUROPE: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 ASIA PACIFIC: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 LATIN AMERICA: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 BA/BE STUDIES 
           7.6.1 INCREASING PATENT EXPIRATION TO INCREASE DEMAND FOR BA/BE STUDIES
                    TABLE 68 MARKET FOR BA/BE STUDIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 69 NORTH AMERICA: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 EUROPE: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 71 ASIA PACIFIC: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 LATIN AMERICA: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE (Page No. - 130)
    8.1 INTRODUCTION 
          TABLE 73 CLINICAL TRIAL SUPPLIES INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    8.2 SMALL-MOLECULE DRUGS 
           8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH
                    TABLE 74 MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 75 NORTH AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 EUROPE: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 ASIA PACIFIC: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 LATIN AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 BIOLOGIC DRUGS 
           8.3.1 RELATIVELY LOW RATE OF ATTRITION OF BIOLOGIC DRUGS COMPARED TO SMALL-MOLECULE DRUGS TO BOOST GROWTH
                    TABLE 79 MARKET FOR BIOLOGIC DRUGS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 80 NORTH AMERICA: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 EUROPE: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 ASIA PACIFIC: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 83 LATIN AMERICA: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 MEDICAL DEVICES 
           8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO SUPPORT GROWTH
                    TABLE 84 MARKET FOR MEDICAL DEVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 85 NORTH AMERICA: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 86 EUROPE: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 87 ASIA PACIFIC: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 88 LATIN AMERICA: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA (Page No. - 141)
    9.1 INTRODUCTION 
          TABLE 89 CLINICAL TRIAL SUPPLIES INDUSTRY, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
    9.2 ONCOLOGY 
           9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH
                    FIGURE 32 US CANCER INCIDENCE IN MALES, BY TYPE (2022)
                    FIGURE 33 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022)
                    FIGURE 34 GLOBAL ONCOLOGY-RELATED CLINICAL TRIALS, 2010–2021 (THOUSAND)
                    TABLE 90 NEW FDA-APPROVED ONCOLOGY DRUGS (2023)
                    TABLE 91 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 92 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 93 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 94 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 95 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 INFECTIOUS DISEASES 
           9.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ACCELERATE EFFORTS TO DEVELOP NEW DRUGS
                    TABLE 96 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 97 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 98 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 99 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 100 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 NEUROLOGY 
           9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR NEUROLOGY RESEARCH TO DRIVE GROWTH
                    TABLE 101 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
                    TABLE 102 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 103 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 104 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 105 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 106 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 METABOLIC DISORDERS 
           9.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH
                    FIGURE 35 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
                    TABLE 107 MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 108 NORTH AMERICA: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 109 EUROPE: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 110 ASIA PACIFIC: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 111 LATIN AMERICA: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.6 IMMUNOLOGY 
           9.6.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL DEMAND FOR CLINICAL TRIAL SUPPLIES
                    TABLE 112 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
                    TABLE 113 MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 114 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 115 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 116 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 117 LATIN AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.7 CARDIOLOGY 
           9.7.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH
                    TABLE 118 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023)
                    TABLE 119 MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 120 NORTH AMERICA: MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 121 EUROPE: MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 122 ASIA PACIFIC: MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 123 LATIN AMERICA: MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.8 GENETIC & RARE DISEASES 
           9.8.1 INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE DEMAND
                    TABLE 124 MARKET FOR GENETIC & RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 125 NORTH AMERICA: MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 126 EUROPE: MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 127 ASIA PACIFIC: MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 128 LATIN AMERICA: MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.9 OTHER THERAPEUTIC AREAS 
          TABLE 129 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)
          TABLE 130 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 131 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 132 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 133 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 134 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER (Page No. - 173)
     10.1 INTRODUCTION 
             TABLE 135 CLINICAL TRIAL SUPPLIES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.2.1 INCREASING OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMA & BIOTECH COMPANIES TO BOOST MARKET
                        TABLE 136 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 137 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 138 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 139 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 140 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.3 CONTRACT RESEARCH ORGANIZATIONS 
             10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS
                        TABLE 141 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 142 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 143 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 144 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 145 LATIN AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
     10.4 MEDICAL DEVICE COMPANIES 
             10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET
                        TABLE 146 MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 147 NORTH AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 148 EUROPE: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 149 ASIA PACIFIC: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 150 LATIN AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION (Page No. - 183)
     11.1 INTRODUCTION 
             TABLE 151 CLINICAL TRIAL SUPPLIES INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 36 NORTH AMERICA: MARKET SNAPSHOT
             TABLE 152 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 153 NORTH AMERICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 154 NORTH AMERICA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
             TABLE 155 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 156 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 157 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Increasing R&D investments to drive market growth in US
                                      TABLE 158 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 159 US: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 160 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 161 US: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 162 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth
                                      TABLE 163 CANADA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 164 CANADA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 165 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 166 CANADA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 167 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             TABLE 168 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 169 EUROPE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 170 EUROPE: MARKET, BY PHASE, 2021–2028 (USD MILLION)
             TABLE 171 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 172 EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 173 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies in Germany
                                      TABLE 174 GERMANY: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 175 GERMANY: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 176 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 177 GERMANY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 178 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth
                                      TABLE 179 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 180 UK: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 181 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 182 UK: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 183 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France
                                      TABLE 184 FRANCE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 185 FRANCE: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 186 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 187 FRANCE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 188 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies in Italy
                                      TABLE 189 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 190 ITALY: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 191 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 192 ITALY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 193 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing biologics production to support market growth in Spain
                                      TABLE 194 SPAIN: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 195 SPAIN: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 196 SPAIN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 197 SPAIN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 198 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 SWITZERLAND
                        11.3.6.1 Growing R&D efforts to provide growth opportunities for clinical trial supplies market in Switzerland
                                      TABLE 199 SWITZERLAND: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 200 SWITZERLAND: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 201 SWITZERLAND: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 202 SWITZERLAND: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 203 SWITZERLAND: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 NETHERLANDS
                        11.3.7.1 Increasing pharmaceutical production to boost market in Netherlands
                                      TABLE 204 NETHERLANDS: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 205 NETHERLANDS: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 206 NETHERLANDS: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 207 NETHERLANDS: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 208 NETHERLANDS: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.8 REST OF EUROPE
                        TABLE 209 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 210 REST OF EUROPE: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 211 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 212 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 213 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.9 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             FIGURE 37 ASIA PACIFIC: MARKET SNAPSHOT
             TABLE 214 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 215 ASIA PACIFIC: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 216 ASIA PACIFIC: MARKET, BY PHASE, 2021–2028 (USD MILLION)
             TABLE 217 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 218 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 219 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Favorable government regulations to boost market growth in China
                                      TABLE 220 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 221 CHINA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 222 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 223 CHINA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 224 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Government initiatives for drug innovation to support market growth
                                      TABLE 225 JAPAN: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 226 JAPAN: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 227 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 228 JAPAN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 229 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Low manufacturing costs and skilled workforce to attract outsourcing and investments to India
                                      TABLE 230 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 231 INDIA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 232 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 233 INDIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 234 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Presence of many research institutes conducting clinical trials to boost market growth
                                      TABLE 235 AUSTRALIA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 236 AUSTRALIA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 237 AUSTRALIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 238 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 239 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Government investments to contribute to market growth in South Korea
                                      TABLE 240 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 241 SOUTH KOREA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 242 SOUTH KOREA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 243 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 244 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 SINGAPORE
                        11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore
                                      TABLE 245 SINGAPORE: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 246 SINGAPORE: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 247 SINGAPORE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 248 SINGAPORE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 249 SINGAPORE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 250 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 251 REST OF ASIA PACIFIC: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 252 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 253 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 254 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.8 ASIA PACIFIC: RECESSION IMPACT
     11.5 LATIN AMERICA 
             TABLE 255 LATIN AMERICA: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
             TABLE 256 LATIN AMERICA: MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 257 LATIN AMERICA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
             TABLE 258 LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 259 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 260 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Growth in pharmaceutical R&D to support market growth
                                      TABLE 261 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 262 BRAZIL: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 263 BRAZIL: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 264 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 265 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Growing number of Phase III clinical trials to drive market growth
                                      TABLE 266 MEXICO: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 267 MEXICO: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                      TABLE 268 MEXICO: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 269 MEXICO: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 270 MEXICO: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 271 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 272 REST OF LATIN AMERICA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 273 REST OF LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 274 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 275 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.4 LATIN AMERICA: RECESSION IMPACT
     11.6 MIDDLE EAST 
             11.6.1 GROWING PRESENCE OF PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
                        TABLE 276 MIDDLE EAST: MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 277 MIDDLE EAST: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 278 MIDDLE EAST: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 279 MIDDLE EAST: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 280 MIDDLE EAST: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.2 MIDDLE EAST: RECESSION IMPACT
     11.7 AFRICA 
             11.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH
                        TABLE 281 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)
                        TABLE 282 AFRICA: MARKET, BY PHASE, 2021–2028 (USD MILLION)
                        TABLE 283 AFRICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 284 AFRICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 285 AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.7.2 AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 268)
     12.1 INTRODUCTION 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 38 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
             TABLE 286 CLINICAL TRIAL SUPPLIES INDUSTRY: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX 
             FIGURE 41 CLINICAL TRIAL SUPPLIES INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
     12.6 COMPANY FOOTPRINT 
             12.6.1 SERVICE FOOTPRINT OF TOP 25 COMPANIES
                        TABLE 287 CLINICAL TRIAL SUPPLIES INDUSTRY: COMPANY SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
             12.6.2 REGIONAL FOOTPRINT OF TOP 25 COMPANIES
                        TABLE 288 CLINICAL TRIAL SUPPLIES INDUSTRY: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
     12.7 COMPANY EVALUATION MATRIX: START-UPS/SMES 
             FIGURE 42 CLINICAL TRIAL SUPPLIES INDUSTRY: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 STARTING BLOCKS
             12.7.3 RESPONSIVE COMPANIES
             12.7.4 DYNAMIC COMPANIES
     12.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 
             TABLE 289 CLINICAL TIAL SUPPLIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
             TABLE 290 CLINICAL TRIAL SUPPLIES INDUSTRY: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
     12.9 COMPETITIVE SCENARIO AND TRENDS 
             12.9.1 SERVICES LAUNCHES & APPROVALS
                        TABLE 291 CLINICAL TRIAL SUPPLIES INDUSTRY: SERVICE LAUNCHES, JANUARY 2021–AUGUST 2023
             12.9.2 DEALS
                        TABLE 292 CLINICAL TRIAL SUPPLIES INDUSTRY: DEALS, JANUARY 2021–JULY 2023
             12.9.3 OTHER DEVELOPMENTS
                        TABLE 293 CLINICAL TRIAL SUPPLIES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2023
 
13 COMPANY PROFILES (Page No. - 283)
(Business overview, Services offered, Recent Developments, MNM view)*
     13.1 KEY MARKET PLAYERS 
             13.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             13.1.2 CATALENT, INC.
                        TABLE 295 CATALENT, INC.: BUSINESS OVERVIEW
                        FIGURE 44 CATALENT, INC.: COMPANY SNAPSHOT (2022)
             13.1.3 EUROFINS SCIENTIFIC
                        TABLE 296 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 45 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             13.1.4 PIRAMAL PHARMA SOLUTIONS
                        TABLE 297 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
                        FIGURE 46 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
             13.1.5 PRA HEALTH SCIENCES (A SUBSIDIARY OF ICON PLC)
                        TABLE 298 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
                        FIGURE 47 ICON PLC: COMPANY SNAPSHOT (2022)
             13.1.6 MARKEN (A SUBSIDIARY OF UPS)
                        TABLE 299 UPS: BUSINESS OVERVIEW
                        FIGURE 48 UPS: COMPANY SNAPSHOT (2022)
             13.1.7 PAREXEL INTERNATIONAL (MA) CORPORATION
                        TABLE 300 PAREXEL INTERNATIONAL (MA) CORPORATION: BUSINESS OVERVIEW
             13.1.8 BIOCAIR
                        TABLE 301 BIOCAIR: BUSINESS OVERVIEW
             13.1.9 ALMAC GROUP
                        TABLE 302 ALMAC GROUP: BUSINESS OVERVIEW
             13.1.10 SHARP SERVICES, LLC
                        TABLE 303 SHARP SERVICES, LLC: BUSINESS OVERVIEW
             13.1.11 PCI PHARMA SERVICES
                        TABLE 304 PCI PHARMA SERVICES: BUSINESS OVERVIEW
             13.1.12 NUVISAN
                        TABLE 305 NUVISAN: BUSINESS OVERVIEW
             13.1.13 LONZA GROUP
                        TABLE 306 LONZA GROUP: BUSINESS OVERVIEW
                        FIGURE 49 LONZA GROUP: COMPANY SNAPSHOT (2022)
     13.2 OTHER PLAYERS 
             13.2.1 OCT GROUP LLC
             13.2.2 COREX LOGISTICS LIMITED
             13.2.3 ACNOS PHARMA GMBH
             13.2.4 CLINICAL SERVICES INTERNATIONAL
             13.2.5 KLIFO
             13.2.6 CLINIGEN LIMITED
             13.2.7 ANCILLARE LP
             13.2.8 N-SIDE
             13.2.9 ADALLEN PHARMA
             13.2.10 DURBIN
             13.2.11 RECIPHARM AB
             13.2.12 IPS PHARMA
 
*Details on Business overview, Services offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 333)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the clinical trial supplies market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the clinical trial supplies market. The secondary sources used for this study include Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Food and Drug Administration (FDA), Committee for Medicinal Products for Human Use (CHMP), ClinicalTrials.gov, Association of Clinical Research Professionals (ACRP), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR), American Federation for Medical Research (AFMR), World Health Organization (WHO), Indian Society for Clinical Research (ISCR), Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA), Annual Reports, SEC Filings, Investor Presentations, Press Releases, Conferences, Journals, Expert Interviews, and MarketsandMarkets Analysis

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Clinical Trial Supplies Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the clinical trial supplies market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the clinical trial supply service business of players operating in the market have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Market Size Estimation Methodology-Bottom-up approach

Clinical Trial Supplies Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach-

Clinical Trial Supplies Market Size, and Share

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The clinical trial supplies market includes the supply services which are required throughout the process of new drug development. And these services are provided either as end-to-end services throughout the drug development process or as a part of the supply chain of clinical trial supplies.

Key Stakeholders

  • Pharmaceutical and biopharmaceutical companies
  • Companies Developing Medical Devices
  • Manufacturers of clinical trial supplies
  • Contract manufacturing organizations (CMOs)
  • Life science research institutes
  • Venture Capitalists
  • Research and consulting firms

Report Objectives

  • To define, describe, and forecast the clinical trial supplies market by service, type, phase, therapeutic area, end user and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall clinical trial supplies market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and the Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product launches, acquisitions partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Service Analysis

  • Service matrix, which provides a detailed comparison of the service portfolio of each company in the Clinical Trial Supplies Market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 3772
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Clinical Trial Supplies Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback